Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151606 | 0.95 | FDPS (0.38) | FDPSSMPD1CA1 | |
| SCHEMBL2941260 | 0.84 | FDPS (0.41) | FDPSSMPD1LAP3PLA2G2ALPAR3 | |
| SCHEMBL5326687 | 0.83 | GPR84 (0.47) | FDPSSMPD1LAP3GPR84FFAR1 | |
| SCHEMBL9000615 | 0.83 | POLB (0.42) | FDPSSMPD1LAP3PLA2G2ALPAR3 | |
| SCHEMBL13924959 | 0.83 | GPR84 (0.47) | FDPSSMPD1LAP3GPR84FFAR1 | |
| SCHEMBL4229201 | 0.83 | GPR84 (0.47) | FDPSSMPD1LAP3GPR84FFAR1 | |
| SCHEMBL2940140 | 0.83 | SMPD1 (0.43) | FDPSSMPD1LAP3PLA2G2ALPAR3 | |
| SCHEMBL9234014 | 0.81 | SMPD1 (0.42) | FDPSSMPD1LAP3PLA2G2ALPAR3 | |
| SCHEMBL3107682 | 0.81 | SMPD1 (0.42) | FDPSSMPD1LAP3PLA2G2ALPAR3 | |
| SCHEMBL3674519 | 0.81 | SMPD1 (0.42) | FDPSSMPD1LAP3PLA2G2ALPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2152658-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | CYP2A13, CYP1A1, CYP1B1 | FDPS 239/4885SMPD1 1679/4885LAP3 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.